Johns Hopkins ABX Guide
Sofosbuvir + Ledipasvir
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
- Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
- Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 31, 2016
Citation
Smith, Janessa M. "Sofosbuvir + Ledipasvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2016. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540671/all/Sofosbuvir_+_Ledipasvir.
Smith JM. Sofosbuvir + Ledipasvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2016. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540671/all/Sofosbuvir_+_Ledipasvir. Accessed June 5, 2023.
Smith, J. M. (2016). Sofosbuvir + Ledipasvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540671/all/Sofosbuvir_+_Ledipasvir
Smith JM. Sofosbuvir + Ledipasvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2016. [cited 2023 June 05]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540671/all/Sofosbuvir_+_Ledipasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir + Ledipasvir
ID - 540671
A1 - Smith,Janessa,PharmD, BCPS
Y1 - 2016/07/31/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540671/all/Sofosbuvir_+_Ledipasvir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
